Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Spironolactone

FDA-approved product (tablet, oral), marketed as Aldactone, Carospir, Spironolactone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Spironolactone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Ascites
  • Cardiovascular disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Essential hypertension
  • Heart failure
  • Hepatic fibrosis
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia
  • Primary hyperaldosteronism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Aldosterone Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Spironolactone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Spironolactone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

    NCT02285920 · start 2014-11

    Registered record
    Registry ID
    NCT02285920
    Conditions
    End-Stage Renal Disease
    Interventions
    Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-11
    Completion
    2017-07-30
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd-Stage Renal Disease
    InterventionSpironolactone
    PhasePhase 2
    Registry statusCompleted

  • Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

    NCT03744767 · start 2014-09-19

    Registered record
    Registry ID
    NCT03744767
    Conditions
    Neovascular Age-related Macular Degeneration
    Interventions
    Spironolactone 50 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09-19
    Completion
    2015-09-22
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeovascular Age-related Macular Degeneration
    InterventionSpironolactone 50 MG
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

    NCT02232880 · start 2014-08

    Registered record
    Registry ID
    NCT02232880
    Conditions
    Hypertension
    Interventions
    Abatacept; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-08
    Completion
    2015-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAbatacept; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients

    NCT02200822 · start 2014-07

    Registered record
    Registry ID
    NCT02200822
    Conditions
    Heart Failure (HF)
    Interventions
    beta blockers; RAAS blockers
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure (HF)
    Interventionbeta blockers; RAAS blockers
    PhasePhase 4
    Registry statusCompleted

  • Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension

    NCT01260857 · start 2013-03

    Registered record
    Registry ID
    NCT01260857
    Conditions
    Hypertension
    Interventions
    Aldazide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2013-03
    Completion
    2015-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAldazide
    PhaseNot recorded
    Registry statusWithdrawn

  • Remission From Stage D Heart Failure

    NCT01774656 · start 2013-01

    Registered record
    Registry ID
    NCT01774656
    Conditions
    Heart Failure NYHA Class III; Heart Failure NYHA Class IV
    Interventions
    Pharmacological Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2017-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure NYHA Class III; Heart Failure NYHA Class IV
    InterventionPharmacological Treatment
    PhasePhase 4
    Registry statusUnknown

  • Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

    NCT02575963 · start 2012-10

    Registered record
    Registry ID
    NCT02575963
    Conditions
    AML
    Interventions
    Cytarabine (Phase 1 only); Lintuzumab-Ac225; Furosemide (Phase 1 only); Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2020-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML
    InterventionCytarabine (Phase 1 only); Lintuzumab-Ac225; Furosemide (Phase 1 only); Spironolactone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Renal Denervation in Refractory Hypertension

    NCT01560312 · start 2011-10

    Registered record
    Registry ID
    NCT01560312
    Conditions
    Hypertension; Resistant to Conventional Therapy
    Interventions
    Renal denervation (Symplicity® Catheter System™)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-10
    Completion
    2014-02
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Resistant to Conventional Therapy
    InterventionRenal denervation (Symplicity® Catheter System™)
    PhasePhase 3
    Registry statusTerminated

  • Spironolactone Against Anthracycline-induced Cardiomyopathy

    NCT02053974 · start 2011-09

    Registered record
    Registry ID
    NCT02053974
    Conditions
    Anthracycline Induced Cardiotoxicity
    Interventions
    Spironolactone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnthracycline Induced Cardiotoxicity
    InterventionSpironolactone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Effects of Spironolactone in Dialysis

    NCT01128101 · start 2011-03

    Registered record
    Registry ID
    NCT01128101
    Conditions
    Renal Failure
    Interventions
    Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-03
    Completion
    2013-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Failure
    InterventionSpironolactone
    PhasePhase 4
    Registry statusUnknown

  • Aldosterone in Diabetic Nephropathy

    NCT00870402 · start 2009-03

    Registered record
    Registry ID
    NCT00870402
    Conditions
    Diabetic Nephropathy
    Interventions
    Spironolactone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-03
    Completion
    2010-03
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    InterventionSpironolactone; Placebo
    PhasePhase 4
    Registry statusUnknown

  • STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)

    NCT00637078 · start 2008-02

    Registered record
    Registry ID
    NCT00637078
    Conditions
    Hypertension; Hypercholesterolemia
    Interventions
    Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Hypercholesterolemia
    InterventionTreatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide
    PhasePhase 4
    Registry statusCompleted

  • Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

    NCT00879060 · start 2007-11

    Registered record
    Registry ID
    NCT00879060
    Conditions
    Myocardial Fibrosis; Hypertrophic Cardiomyopathy
    Interventions
    Spironolactone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-11
    Completion
    2012-11
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Fibrosis; Hypertrophic Cardiomyopathy
    InterventionSpironolactone; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death

    NCT00524862 · start 2007-10

    Registered record
    Registry ID
    NCT00524862
    Conditions
    Coronary Heart Disease; Congestive Heart Failure; Ventricular Dysfunction; Low Cardiac Output; Sudden Cardiac Death
    Interventions
    Optimized medical therapy; Implantable Cardioverter Defibrillator
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2007-10
    Completion
    2011-04
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease; Congestive Heart Failure; Ventricular Dysfunction; Low Cardiac Output +1 more
    InterventionOptimized medical therapy; Implantable Cardioverter Defibrillator
    PhaseNot applicable
    Registry statusTerminated

  • Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss

    NCT00175617 · start 2005-09

    Registered record
    Registry ID
    NCT00175617
    Conditions
    Female Pattern Hair Loss
    Interventions
    Spironolactone; Minoxidil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2009-03-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemale Pattern Hair Loss
    InterventionSpironolactone; Minoxidil
    PhasePhase 2
    Registry statusCompleted